ArticleBMC women's health2026

Twenty-four months progression-free survival (ongoing) for treatment of recurrent ovarian clear cell carcinoma with surufatinib in combination with toripalimab: a case report.

Siyi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.